openPR Logo
Press release

Colorectal Cancer Drugs Market 2024: Growth, Trends, Analysis, Forecast 2033

07-12-2024 09:11 AM CET | Health & Medicine

Press release from: The Business Research Company

Colorectal Cancer Drugs Market 2024: Growth, Trends, Analysis,

"The new report published by The Business Research Company, titled ""Colorectal Cancer Drugs Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the colorectal cancer drugs market size has grown strongly in recent years. It will grow from $19.51 billion in 2023 to $20.74 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The colorectal cancer drugs market size is expected to see strong growth in the next few years. It will grow to $26.39 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=2590&type=smp

Rising Demand For Personalized Medicines Drives Growth In Colorectal Cancer Drugs Market
The increasing demand for personalized medicines is expected tom propel the growth of the colorectal cancer drugs market going forward. Personalized medicine, also known as precision medicine, is an approach to medical treatment and healthcare that takes into account individual variations in patients' genes, environments, and lifestyles. Personalized medicine is transforming the approach to CRC treatment, offering more individualized and effective care for patients. It is likely to continue driving the growth of the CRC drug market as research and drug development efforts become more tailored to specific genetic and molecular profiles. For instance, in October 2022, according to reports published by STAT, a US-based health-oriented news company, there were more than 75,000 genetic testing products and 300 personalized medicines. Therefore, the increasing demand for personalized medicine is driving the growth of the colorectal cancer drugs market.

Advancements In Targeted Therapies For Metastatic Colorectal Cancer
Targeted therapies have already begun to extend the lifespan of metastatic Colorectal cancer patients compared with chemotherapy-only therapy. Target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells while sparing the toxicity to off-target cells. Opdivo and Keytruda are examples of targeted therapies.

The colorectal cancer drugs market covered in this report is segmented -
1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators
2) By Class: Immunotherapy, Chemotherapy, Other Classes
3) By Distribution Channels: Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=2590&type=discount

Major companies operating in the colorectal cancer drugs market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Danaher Corporation, Eli Lilly and Company, Amgen Inc., Siemens Healthineers AG, Astellas Pharma Inc., Servier Laboratories, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Ipsen SA, Taiho Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Metabiomics Corporation, Randox Laboratories, Taiho Oncology Inc., EDP Biotech Corporation, Genomic Tree Inc., Ono Pharmaceutical Co. Ltd., Epigenomics AG, Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mundipharma International Limited, Teva Pharmaceutical Industries Ltd., Biogen Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Spectrum Pharmaceuticals Inc., Exelixis Inc., Seattle Genetics Inc., Incyte Corporation, Clovis Oncology Inc., Karyopharm Therapeutics Inc.

Contents of the report:
1. Executive Summary
2. Colorectal Cancer Drugs Market Report Structure
3. Colorectal Cancer Drugs Market Trends And Strategies
4. Colorectal Cancer Drugs Market - Macro Economic Scenario
5. Colorectal Cancer Drugs Market Size And Growth
…..
27. Colorectal Cancer Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Colorectal Cancer Drugs Market 2024: Growth, Trends, Analysis, Forecast 2033 here

News-ID: 3577988 • Views:

More Releases from The Business Research Company

Company Registration Service Market Landscape 2025: Forecast Data and Growth Strategy Insights
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Company Registration Service Market Through 2025? The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecasts, and Growth Drivers
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025? In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market in 2025: Advancement In Digital Insurance Platforms Transforms Small And Medium Enterprises Coverage With Integrated, Data-Driven Solutions
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025? The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due To Rising Environmental Monitoring Requirements: Strengthening the Growth Trajectory of the Combustion Emissions Analyzer Market
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025? In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth

All 5 Releases


More Releases for Colorectal

Metastatic Colorectal Cancer Therapeutics Market - Innovation in Motion: Elevate …
Newark, New Castle, USA: The "Metastatic Colorectal Cancer Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Metastatic Colorectal Cancer Therapeutics Market: https://www.growthplusreports.com/report/metastatic-colorectal-cancer-therapeutics-market/8685 This latest report researches the
Potential Opportunities of Colorectal Cancer Therapeutics Market
The global colorectal cancer therapeutics market size is projected to reach USD 16.58 billion by 2026, owing to the rise in the prevalence of colorectal cancer worldwide. A report by Fortune Business Insights(TM) titled, "Colorectal Cancer Therapeutics Market Size, Share & Industry Analysis, By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Others), By Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and
Colorectal Cancer Pipeline Therapeutic Review H1 2017
Colorectal Cancer Pipeline Review H1 2017 provides an overview of the Colorectal Cancer (Oncology) pipeline landscape. Colorectal cancer is cancer that starts in the large intestine (Colorectal). There is no single cause of colorectal cancer. Nearly all colorectal cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. For More on Colorectal Cancer Pipeline Review H1 2017 Report Inquire @ https://goo.gl/1HQ4Fn . Report Description: Pharmaceutical guide Colorectal Cancer - Pipeline Review H1
US Colorectal Cancer Drug Pipeline Analysis
Among all the regions affected with colorectal cancer, the US would continue to account for a giant’s share owing to its huge population base. With regards to rates of increase, it is most likely that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions of the disease. According to estimates, approximately 55,000 people die
Colorectal Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Colorectal Cancer - Heat Map and Analysis to its growing collection of premium market research reports. Colorectal cancer (CRC), otherwise known as bowel cancer, is a malignancy originating in the colon (the large intestine) or rectum, both of which are located towards the end of the human gastrointestinal tract. It begins as a benign tumor, which is almost always in
Colorectal Cancer Treatment Market- Global Outlook 2024
Colorectal cancer is cancer that starts in the colon or rectum. The colon and the rectum are parts of the large intestine, which is the lower part of the body’s digestive system. The colon absorbs water and nutrients from the food and stores waste matter (stool). Stool moves from the colon into the rectum before it leaves the body. Colorectal cancer often begins as a growth called a polyp, which